| MeSH term | MeSH ID | Detail |
|---|---|---|
| Leishmaniasis, Visceral | D007898 | 13 associated lipids |
| Radiation Injuries | D011832 | 14 associated lipids |
| Encephalitis | D004660 | 15 associated lipids |
| HIV Seropositivity | D006679 | 15 associated lipids |
| Synovitis | D013585 | 15 associated lipids |
| Bronchial Hyperreactivity | D016535 | 15 associated lipids |
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Dermatomycoses | D003881 | 17 associated lipids |
| Ischemia | D007511 | 18 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Butt AA | Cervical adenitis due to Mycobacterium fortuitum in patients with acquired immunodeficiency syndrome. | 1998 | Am. J. Med. Sci. | pmid:9427575 |
| Feldman C et al. | Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. | 1997 | Inflammation | pmid:9429912 |
| Stone GG et al. | Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. | 1996 | Helicobacter | pmid:9432314 |
| McLaren A et al. | The role of ranitidine bismuth citrate in significantly reducing the emergence of Helicobacter pylori strains resistant to antibiotics. | 1997 | Helicobacter | pmid:9432317 |
| Bardhan KD et al. | Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. | 1997 | Helicobacter | pmid:9432318 |
| Takimoto T et al. | The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients. | 1997 | Helicobacter | pmid:9432334 |
| Pieramico O et al. | Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial. | 1997 | Helicobacter | pmid:9432335 |
| Pounder RE et al. | Ranitidine bismuth citrate with clarithromycin for the eradication of Helicobacter pylori and for ulcer healing. | 1997 | Helicobacter | pmid:9432341 |
| Reisner BS et al. | Electron microscopic analysis of Mycobacterium avium complex isolates exposed to ciprofloxacin, rifabutin, ethambutol and clarithromycin. | 1997 | Int. J. Tuberc. Lung Dis. | pmid:9432376 |
| Lerang F et al. | Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy. | 1997 | Scand. J. Gastroenterol. | pmid:9438318 |
| Akiyama H et al. | Biofilm formation of Staphylococcus aureus strains isolated from impetigo and furuncle: role of fibrinogen and fibrin. | 1997 | J. Dermatol. Sci. | pmid:9438901 |
| Bazzoli F and Pozzato P | Therapy of H. pylori infection. | 1997 | J. Physiol. Pharmacol. | pmid:9440054 |
| Dixon JS et al. | Ranitidine bismuth citrate plus clarithromycin for the eradication of H. pylori. | 1997 | J. Physiol. Pharmacol. | pmid:9440055 |
| Yatsunami J et al. | Clarithromycin is a potent inhibitor of tumor-induced angiogenesis. | 1997 | Res Exp Med (Berl) | pmid:9440137 |
| Burman WJ et al. | A retrospective comparison of clarithromycin versus rifampin in combination treatment for disseminated Mycobacterium avium complex disease in AIDS: clarithromycin decreases transfusion requirements. | 1997 | Int. J. Tuberc. Lung Dis. | pmid:9441082 |
| Suzuki K et al. | Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages. | 1997 | Int. J. Tuberc. Lung Dis. | pmid:9441102 |
| Gotoh A et al. | Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori. | 1997 | Microbiol. Immunol. | pmid:9444328 |
| Mikamo H et al. | Effects of long-term/low-dose clarithromycin on neutrophil count and interleukin-8 level in pyometra. | 1998 Jan-Feb | Chemotherapy | pmid:9444409 |
| Prattichizzo FA et al. | [Carditis associated with Mycoplasma pneumoniae infection. Clinical aspects and therapeutic problems]. | 1997 | Minerva Cardioangiol | pmid:9446067 |
| Genné D et al. | Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. | 1997 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:9447898 |
| Fennerty MB | Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. | 1998 | Am. J. Gastroenterol. | pmid:9448162 |
| Forné M et al. | Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. | 1998 | Am. J. Gastroenterol. | pmid:9448170 |
| Bermudez LE et al. | Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. | 1998 | Antimicrob. Agents Chemother. | pmid:9449283 |
| Sax L | Bacterial pharyngitis in children. | 1998 | J Fam Pract | pmid:9451356 |
| Goujard C et al. | Clarithromycin-resistant Mycobacterium avium strain in a clarithromycin-naive AIDS patient. | 1998 | Clin. Infect. Dis. | pmid:9455532 |
| Thornsberry C et al. | Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. | 1997 | Diagn. Microbiol. Infect. Dis. | pmid:9458982 |
| Holmberg SD et al. | Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. | 1998 | JAMA | pmid:9459473 |
| Briant C et al. | Pericarditis as a manifestation of Lyme disease. | 1997 | J Emerg Nurs | pmid:9460386 |
| Misiewicz JJ et al. | One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. | 1997 | Gut | pmid:9462204 |
| Loo VG et al. | In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. | 1997 | J. Antimicrob. Chemother. | pmid:9462442 |
| Hoffner SE et al. | In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. | 1997 | J. Antimicrob. Chemother. | pmid:9462443 |
| Torresani C et al. | Clarithromycin versus doxycycline in the treatment of rosacea. | 1997 | Int. J. Dermatol. | pmid:9466207 |
| Preston SL et al. | Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. | 1998 | AIDS | pmid:9468380 |
| Tzivras M et al. | One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. | 1997 | Eur J Gastroenterol Hepatol | pmid:9471024 |
| Price J and Hamilton W | Pragmatic eradication of H. pylori. | 1997 | Br J Gen Pract | pmid:9474836 |
| Hahn DL et al. | Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma. | 1998 | Ann. Allergy Asthma Immunol. | pmid:9475566 |
| Cammarota G et al. | Regression of a primary gastric MALT lymphoma with extensive antrum lesions by Helicobacter pylori eradication. | 1997 | Ital J Gastroenterol Hepatol | pmid:9476192 |
| Hotz J | [Reflux disease of the gastrointestinal tract. Acute therapy and long-term care in daily practice. 2. Therapeutic procedure--diagnosis--therapy-diagram]. | 1997 | Fortschr. Med. | pmid:9480263 |
| Ridgway GL et al. | The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. | 1997 | J. Antimicrob. Chemother. | pmid:9484871 |
| Igea JM and Lázaro M | Hypersensitivity reaction to clarithromycin. | 1998 | Allergy | pmid:9491242 |
| Hermon-Taylor J et al. | Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease. | 1998 | BMJ | pmid:9492675 |
| Kondoh K and Hashiba M | [Inhibitory effect of macrolide antibiotics on biofilm formation by Pseudomonas aeruginosa]. | 1998 | Nippon Jibiinkoka Gakkai Kaiho | pmid:9493436 |
| Boixeda de Miquel D | [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer]. | 1997 | Rev Esp Enferm Dig | pmid:9494374 |
| Pérez Mota A et al. | Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules. | 1997 | Rev Esp Enferm Dig | pmid:9494375 |
| Payen MC et al. | [Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection]. | 1997 | Rev Mal Respir | pmid:9496599 |
| Kusuhara H et al. | Evaluation of combined antibiotic-omeprazole therapies in Helicobacter pylori-infected Mongolian gerbils. | 1998 | J. Gastroenterol. | pmid:9497215 |
| Dubois A et al. | Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates. | 1998 | J. Gastroenterol. | pmid:9497216 |
| Hocqueloux L et al. | Pulmonary Mycobacterium avium complex disease without dissemination in HIV-infected patients. | 1998 | Chest | pmid:9498982 |
| Ziering W and McElvaine P | Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. | 1998 Jan-Feb | Infection | pmid:9505188 |
| Rosina P et al. | Fixed drug eruption from clarithromycin. | 1998 | Contact Derm. | pmid:9506224 |
| Carlson LD et al. | Standardized BACTEC method to measure clarithromycin susceptibility of Mycobacterium genavense. | 1998 | J. Clin. Microbiol. | pmid:9508306 |
| Sato K et al. | Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. | 1998 | J. Antimicrob. Chemother. | pmid:9511040 |
| Moayyedi P | Amoxycillin dual therapy against Helicobacter pylori--the final nail in the coffin? | 1997 | Ital J Gastroenterol Hepatol | pmid:9513823 |
| Williamson R et al. | New options in Helicobacter pylori eradication: efficacy, resistance and synergy. | 1998 | Scand. J. Gastroenterol. Suppl. | pmid:9515751 |
| Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. | 1998 | Am. J. Gastroenterol. | pmid:9517644 |
| Adamek RJ et al. | Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. | 1998 | Am. J. Gastroenterol. | pmid:9517645 |
| Trevisani L et al. | A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. | 1998 | Am. J. Gastroenterol. | pmid:9517646 |
| Hafner R et al. | Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. | 1998 | Antimicrob. Agents Chemother. | pmid:9517944 |
| Fattorini L et al. | Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. | 1998 | Antimicrob. Agents Chemother. | pmid:9517960 |
| Trivedi S et al. | Clarithromycin and digoxin toxicity. | 1998 | Ann. Intern. Med. | pmid:9518419 |
| Laine L and Fendrick AM | Helicobacter pylori and peptic ulcer disease. Bridging the gap between knowledge and treatment. | 1998 | Postgrad Med | pmid:9519040 |
| Alegre Herrera S et al. | [Clarithromycin-carbamazepine interaction: neurological symptoms and hyponatremia]. | 1998 | An Med Interna | pmid:9522506 |
| Berquist WE | New, improved Helicobacter pylori eradication therapy in children. | 1998 | J. Pediatr. Gastroenterol. Nutr. | pmid:9523877 |
| Collins LA et al. | Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 | Antimicrob. Agents Chemother. | pmid:9527783 |
| Kashuba AD and Amsden GW | Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9527816 |
| Gisbert JP et al. | [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic]. | 1998 | Med Clin (Barc) | pmid:9527978 |
| Perng CL et al. | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. | 1998 | Dig. Dis. Sci. | pmid:9539638 |
| Oberg KC | Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. | 1998 Mar-Apr | Pharmacotherapy | pmid:9545160 |
| Treiber G et al. | Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. | 1998 | Helicobacter | pmid:9546119 |
| Suzuki J et al. | Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. | 1998 | Helicobacter | pmid:9546120 |
| Lindsetmo RO et al. | Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy. | 1998 | Scand. J. Gastroenterol. | pmid:9548613 |
| Comet R et al. | [Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection]. | 1998 | Gastroenterol Hepatol | pmid:9549183 |
| Carnicer J | [Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?]. | 1998 | Gastroenterol Hepatol | pmid:9549199 |
| Iwata M et al. | [Three cases of Fitz-Hugh-Curtis syndrome detected in the early stage by abdominal ultrasonography]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9549331 |
| Scheen AJ | [Drug clinics. The drug of the month. Ranitidine bismuth citrate (Pylorid)]. | 1998 | Rev Med Liege | pmid:9555183 |
| Cheng KL et al. | Effect of grapefruit juice on clarithromycin pharmacokinetics. | 1998 | Antimicrob. Agents Chemother. | pmid:9559810 |
| Hoppe JE and Bryskier A | In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). | 1998 | Antimicrob. Agents Chemother. | pmid:9559823 |
| Sonnenberg A et al. | Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. | 1998 | Arch. Intern. Med. | pmid:9570170 |
| Dal Bo' N et al. | Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks? | 1998 | J. Gastroenterol. Hepatol. | pmid:9570242 |
| O'Connor HJ et al. | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? | 1998 | Aliment. Pharmacol. Ther. | pmid:9570262 |
| Scott BB | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9570263 |
| Jarboe E et al. | Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin. | 1998 | Diagn. Microbiol. Infect. Dis. | pmid:9572027 |
| Elliott RL et al. | Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. | 1998 | J. Med. Chem. | pmid:9572890 |
| Griesgraber G et al. | Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. | 1998 | J. Med. Chem. | pmid:9572891 |
| Malfertheiner P and Blum AL | [Helicobacter pylori infection and ulcer]. | 1998 | Chirurg | pmid:9576033 |
| Lee KL et al. | QT prolongation and Torsades de Pointes associated with clarithromycin. | 1998 | Am. J. Med. | pmid:9576415 |
| Schwartz H et al. | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. | 1998 | Am. J. Gastroenterol. | pmid:9576452 |
| Felmingham D et al. | Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season. | 1998 | J. Antimicrob. Chemother. | pmid:9578171 |
| Tatsis G et al. | Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections. | 1998 | J. Antimicrob. Chemother. | pmid:9579716 |
| Sheu BS et al. | One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy. | 1998 | J. Formos. Med. Assoc. | pmid:9585678 |
| Hasegawa M et al. | [In vitro activities of faropenem against clarithromycin resistance Helicobacter pylori isolates]. | 1998 | Kansenshogaku Zasshi | pmid:9585692 |
| Sousa C et al. | [Cholestatic hepatitis probably induced by clarithromycin]. | 1997 | Gastroenterol. Clin. Biol. | pmid:9587506 |
| Chen S et al. | [Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection]. | 1996 | Zhonghua Nei Ke Za Zhi | pmid:9592303 |
| Liu W et al. | [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. | 1996 | Zhonghua Nei Ke Za Zhi | pmid:9592304 |
| Goldstein EJ et al. | Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. | 1998 | Antimicrob. Agents Chemother. | pmid:9593139 |
| Carr RA et al. | Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. | 1998 | Antimicrob. Agents Chemother. | pmid:9593146 |
| Sörberg M et al. | Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9593154 |
| Spangler SK et al. | Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. | 1998 | Antimicrob. Agents Chemother. | pmid:9593160 |
| van Aarem A et al. | Recurrent therapy resistant mastoiditis by Mycobacterium cheilonae abscessus, a nontuberculous mycobacterium. | 1998 | Int. J. Pediatr. Otorhinolaryngol. | pmid:9596371 |
| Koster F | Paradoxical local response to therapy for Mycobacterium avium complex infection in four patients with AIDS. | 1998 | Clin. Infect. Dis. | pmid:9597260 |